BFH772 (VEGFR2 inhibitor): Technical Use Guide & Protocols

What This Product Solves

BFH772 (CAS 890128-81-1) is a potent small-molecule VEGFR2 kinase inhibitor, providing researchers with a precise tool for modulating VEGFR2-mediated angiogenesis. With an IC₅₀ of 3 nM for VEGFR2 and a demonstrated selectivity profile—showing approximately 500-fold reduced potency against closely related receptors (FLK-1, FLT-1, FLT-4) and about 40-fold lower efficacy against other kinases (B-RAF, RET, TIE-2)—BFH772 is tailored for experiments where off-target kinase inhibition must be minimized (product_spec). This makes it particularly applicable in tumor angiogenesis research, where precise VEGFR2 pathway inhibition is necessary for dissecting the molecular mechanisms of vascular development, tumor progression, and anti-angiogenic strategies.

BFH772 is not suitable for workflows requiring water-soluble compounds or those demanding non-selective (broad-spectrum) kinase inhibition, due to its defined solubility (insoluble in water) and selectivity profile. For such needs, alternative agents should be considered (internal_article).

Protocol Parameters

• assay: VEGFR2 kinase inhibition (in vitro) | value_with_unit: IC₅₀ = 3 nM | applicability: Determining potency in VEGFR2-driven cellular assays | rationale: Ensures high-affinity targeting of VEGFR2 with minimal off-target activity | source_type: product_spec
• assay: Compound solubility for stock solutions | value_with_unit: ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol | applicability: Preparation of concentrated stocks for in vitro and in vivo dosing | rationale: Maximizes compound stability and compatibility with organic solvent-based workflows | source_type: product_spec
• assay: Storage conditions | value_with_unit: -20°C (solid form) | applicability: Maintains chemical integrity and potency for long-term studies | rationale: Prevents degradation and ensures reproducibility across experiments | source_type: product_spec

Workflow Setup and QC Checklist

• Compound Reconstitution: Dissolve BFH772 in DMSO or ethanol to prepare concentrated stock solutions. Verify full dissolution by visual inspection and, if available, HPLC analysis. Avoid aqueous solvents due to insolubility and risk of precipitation (source: product_spec).
• Aliquoting and Storage: Prepare single-use aliquots to limit freeze-thaw cycles. Store solid and solutions at -20°C. Do not store solutions long-term; prepare fresh dilutions for each experiment (source: product_spec).
• Quality Control: Confirm compound identity and purity using provided certificates of analysis (purity >96%), and reference the batch-specific safety data sheet (source: product_spec).
• Assay Design: Select cell lines or in vivo models reliant on VEGFR2 signaling. Review literature on VEGFR2 pathway dependency for chosen models, and avoid using this agent where off-target kinase activity is necessary (internal_article).
• Solvent Compatibility: Validate that DMSO or ethanol at working concentrations are tolerated by your biological system. Adjust vehicle controls accordingly to match the highest solvent concentration used.

Common Failure Modes and Fixes

• Precipitation in Media: BFH772 is insoluble in water. If precipitation occurs after dilution, increase organic solvent percentage within cell- or animal-safe limits. Always filter solutions before use if precipitation is suspected.
• Reduced Activity Over Time: Long-term storage of solutions is not recommended due to potential degradation. Always prepare fresh working solutions from frozen aliquots immediately before use.
• Off-Target Effects: Although BFH772 is highly selective, at high concentrations it may inhibit other kinases with reduced efficacy. Maintain concentrations within the recommended range for VEGFR2 inhibition and include appropriate controls.
• Batch Variability: Always reference the specific batch’s certificate of analysis and confirm purity before use. If unexpected biological effects are observed, verify compound integrity by HPLC or mass spectrometry where possible.

Scope and Limitations

• Selective Use: The compound’s selectivity profile makes it suitable for studies where VEGFR2-specific inhibition is desired, such as dissecting VEGFR2-mediated angiogenic processes in tumor models (internal_article).
• Solvent Constraints: Incompatibility with water restricts its use to workflows amenable to organic solvents. It is unsuitable for high-throughput screens or assays requiring direct aqueous delivery.
• Broad-Spectrum Inhibition: BFH772 should not be chosen for workflows needing broad kinase inhibition, as its off-target activity against other kinases is substantially lower (source: product_spec).
• Translation to Clinical Studies: While in vivo data support tumor growth and angiogenesis inhibition, and clinical evaluation is ongoing for rosacea, the product is intended strictly for research use and not for direct clinical application.

Conclusion

BFH772 is a rigorously characterized VEGFR2 signaling pathway inhibitor, ideal for protocols requiring high selectivity and organic solvent compatibility. Researchers should strictly adhere to recommended reconstitution and storage parameters to maximize performance. The product’s detailed quality control and supporting documentation, available from APExBIO, facilitate reproducible research outcomes. For further protocol specifics and troubleshooting guidance, consult both the BFH772 (VEGFR2 inhibitor) product page and referenced internal technical articles.